The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Anktiva
nogapendekin alfa inbakicept-pmln · NOGAPENDEKIN ALFA INBAKICEPT-PMLN 400 ug/.4mL · Solution · Intravesical · Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
NDC 81481-0803-01 · 1 VIAL, GLASS in 1 BOX / .4 mL in 1 VIAL, GLASS · BLA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$94.31per billing unit (1 MCG)HCPCS J9028 · Jul 1, 2026
- Part D plans paid (avg)$89,966.84per dosage unitgross, before rebates — matched by drug name · 2024
- Federal ceiling (Big4)$27,344.72per package of 0.4MLAltor BioScience, LLC · Jan 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$35,800.00
Reported to Texas DSHS · 2026 annual filing · Altor BioScience, LLC
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 1 MCG
$94.306
HCPCS J9028 · Jul 1, 2026 quarter · typically ASP + 6%
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- PCI San Diego, Inc.United Statesmanufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $171,466.21 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761336
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of nogapendekin alfa inbakicept-pmln (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc. | NOGAPENDEKIN ALFA INBAKICEPT-PMLN 400 ug/.4mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Anktiva — NDC 81481-0803-01," retrieved September 3, 2026, https://drugdashboards.com/drug/81481080301.
Free to cite with attribution — see how the data is put together.